Welcome to our dedicated page for Kronos Bio news (Ticker: KRON), a resource for investors and traders seeking the latest updates and insights on Kronos Bio stock.
Kronos Bio, Inc. (formerly Nasdaq: KRON) has generated a stream of news centered on its work as a biopharmaceutical and clinical-stage company focused on small molecule therapeutics that address deregulated transcription in cancer and autoimmune diseases. Company announcements describe how its proprietary discovery engine decodes transcription factor regulatory networks to identify druggable cofactors and support oncology and autoimmune programs.
News coverage for KRON has included scientific and pipeline updates, such as preclinical data from p300 lysine acetyltransferase (KAT) inhibitor programs in multiple myeloma, HPV-driven tumors, and autoimmune indications. Releases have detailed how p300 KAT inhibition can modulate pro-inflammatory signaling pathways, influence viral oncogene expression in HPV-driven tumor models, and support candidate selection for conditions such as Sjögren’s disease.
Corporate and strategic developments have also been prominent in Kronos Bio’s news flow. The company has reported decisions to discontinue development of a CDK9 inhibitor in a specific ovarian cancer setting, implement cost reduction strategies and workforce reductions, and evaluate strategic alternatives that could include acquisitions, mergers, or asset sales. These updates provide context on how Kronos Bio has managed its pipeline and resources.
A key news theme for KRON is the company’s acquisition by Concentra Biosciences, LLC. In May 2025, Kronos Bio announced a definitive merger agreement under which a Concentra subsidiary would launch a tender offer for all outstanding shares of Kronos Bio common stock for a cash payment per share plus a non-tradeable contingent value right tied to potential proceeds from specified product candidates and cost savings. A subsequent Form 8-K filed on June 20, 2025, reports that the tender offer was completed and the merger closed, with Kronos Bio becoming a wholly owned subsidiary of Concentra and its shares delisted from Nasdaq.
Investors, researchers, and observers reviewing KRON-related news can use this history to understand Kronos Bio’s scientific focus on deregulated transcription, the evolution of its pipeline, and the sequence of strategic decisions that culminated in its acquisition and delisting. This news archive offers a detailed record of how the company communicated scientific findings, financial results, restructuring measures, and corporate transactions over time.
Kronos Bio, Inc. (Nasdaq: KRON) announced participation in two upcoming investor conferences. On Dec. 2, 2020, at 2:15 p.m. ET, management will engage in a virtual fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference. Additionally, on Dec. 3, 2020, meetings will take place at the Piper Sandler 32nd Annual Virtual Healthcare Conference, featuring a pre-recorded fireside chat available from 10 a.m. ET. The events will be accessible via the company’s website, with replays available for one month.
Kronos Bio, Inc. reported significant advancements in its business on November 18, 2020, including the acquisition of SYK inhibitors from Gilead Sciences and plans for late-stage clinical testing of its lead therapy, entospletinib, for NPM1-mutated acute myeloid leukemia. The company raised $287.5 million from its upsized IPO on October 14, 2020, strengthening its financial position. Despite a net loss of $39.7 million for Q3 2020, Kronos is well-capitalized for ongoing research and development, showing promising growth potential.
Kronos Bio, Inc. (Nasdaq: KRON) announced participation in a fireside chat at the Jefferies Virtual London Healthcare Conference on Nov. 18, 2020, at 7:20 p.m. GMT (2:20 p.m. ET). The event will be streamed live via the company's website, with a replay available for one month after. Kronos Bio focuses on developing therapies for cancer, particularly through targeting dysregulated transcription factors. Their lead investigational therapy, entospletinib, targets spleen tyrosine kinase (SYK) for NPM1-mutated acute myeloid leukemia (AML), and they are also working on KB-0742 for MYC-amplified solid tumors.
Kronos Bio announced promising results for its investigational therapy, KB-0742, targeting castration-resistant prostate cancer (CRPC). In preclinical studies, KB-0742 demonstrated an 82% tumor growth inhibition compared to 70% with standard chemotherapy. This selective CDK9 inhibitor effectively reduced AR-driven transcriptional activity and promoted apoptosis in CRPC cell lines. The company plans to submit an IND by Q4 2020 and initiate a Phase 1/2 clinical trial in 2021. These advancements position KB-0742 as a potential treatment for high MYC-amplification tumors, addressing a significant unmet medical need.
Kronos Bio, Inc. (Nasdaq: KRON) has successfully closed its initial public offering, selling 15,131,579 shares at $19.00 each, including 1,973,684 shares sold through underwriters' option. This offering generated approximately $287.5 million in gross proceeds. The shares commenced trading on Nasdaq on October 9, 2020. Goldman Sachs, Jefferies, Cowen, and Piper Sandler acted as joint book-running managers. The registration statement for these securities was effective as of October 8, 2020.
Kronos Bio, a clinical-stage biopharmaceutical company, has priced its initial public offering (IPO) of 13,157,895 shares at $19.00 per share, aiming to raise approximately $250 million before expenses. The shares are set to trade on the Nasdaq Global Select Market under the symbol 'KRON' starting October 9, 2020, with the offering expected to close on October 14, 2020. The company has granted underwriters a 30-day option to purchase an additional 1,973,684 shares. Goldman Sachs, Jefferies, Cowen, and Piper Sandler are leading the offering.